Sudeep Pharma plans to raise ₹95 crore for capex and expand manufacturing capacity by 50,000 tonnes by March 2026. Despite strong export revenue and profit growth, investors may await post-listing performance due to high customer concentration and increased working capital days. The company seeks a P/E multiple of up to 48.